Application of pro-sphingolipid activator protein (PSAP) in preparation of medicine with effects of inhibiting new vessels and protecting nerves for treating fundus diseases

By using sphingolipids to activate proteogen PSAP and its derived peptides PSAP-A and PSAP-B, the problem of existing anti-VEGF treatment methods being poor in some patients with fundus diseases has been solved, and the inhibition of neovascularization and neuroprotection has been achieved. Shows similar effects to Afepcept and is superior in neuroprotection.

CN118924878APending Publication Date: 2024-11-12SHANGHAI JIAOTONG UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410842451.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-26
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing anti-VEGF treatment methods are not effective in some patients with fundus diseases, and long-term use may destroy the protective effect of VEGF on the optic nerve, leading to the degeneration of optic nerve cells, and it is necessary to develop more effective treatment methods to inhibit neovascularization and neuroprotection.

Method used

Sphingolipid-activated proteogen PSAP and its derived polypeptides PSAP-A and PSAP-B are used as drugs for the treatment of fundus diseases. They are administered through vitreous injection and combined with pharmaceutical excipients to inhibit neovascularization and provide neuroprotection.

Benefits of technology

PSAP showed similar effects on inhibiting neovascularization as afepcept in vitro and in vivo, and had additional neuroprotective effects, which was better than afepcept in antioxidant injury and photodamage, with a greater clinical transformation. value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924878A_ABST
    Figure CN118924878A_ABST
Patent Text Reader

Abstract

The invention discloses an application of PSAP (prosphingolipid activator protein) in preparation of a medicine for treating fundus diseases with effects of inhibiting new vessels and protecting nerves, and the amino acid sequence of the PSAP comes from a Uniport database, an NCBI (National Center of Biotechnology Information) database, an Enmbl database or a PDB database, including but not limited to PSAP-A and PSAP-B, the invention explores and develops the application of the PSAP protein in preparation of the novel fundus medicine, compared with aflibercept, the PSAP protein has an additional neuroprotective effect, namely, an anti-oxidative damage effect and an anti-light damage effect, the invention provides a more effective VEGF treatment medicine or method, the treatment frequency is reduced, and the treatment cost is reduced. Better effects of inhibiting new vessels and protecting nerves are achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biological medicine, and in particular to the use of pro-sphingolipid activating protein (PSAP) as a drug for preparing a drug for treating fundus diseases with the effects of inhibiting neovascularization and protecting nerves. Background Art

[0002] Ophthalmic diseases, such as cataracts, age-related macular degeneration (AMD), diabetic retinopathy (DR), retinal vascular occlusion (RVO), glaucoma and refractive errors, may lead to visual impairment or even blindness. There are many reasons for the above eye problems, such as congenital inheritance, environment, and poor eye habits; among them, aging is the main cause, which will cause many fundus diseases, such as wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO), which are the most common causes of vision loss and even blindness in the elderly. Fundus diseases have a profound impact on the eye health of people of all ages. The treatment and long-term management of fundus diseases put tremendous pressure and burden on the medical system.

[0003] Vascular Endothelial Growth Factor (VEGF) is known to play a key role in the pathological process of fundus diseases. In fundus diseases, due to abnormal regulation of VEGF, new abnormal blood vessels sprout from the choroid and grow into the retina, leading to pathological symptoms. Anti-VEGF therapy is the first-line treatment for fundus diseases. Anti-VEGF drugs, such as ranibizumab, bevacizumab and aflibercept, are significantly effective in reducing vascular leakage and inhibiting vascular proliferation by inhibiting VEGF-related signaling pathways. In this study, the anti-VEGF drug used was aflibercept. Aflibercept is a recombinant fusion protein that contains fragments of Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) and Vascular Endothelial Growth Factor Receptor 2 (VEGFR2). It has a high affinity for all subtypes of vascular endothelial growth factor A (VEGFA). Aflibercept has been approved by the U.S. Food and Drug Administration and is currently the main anti-VEGF drug used clinically worldwide. The clinical "3+PRN" therapy is a standard treatment for patients with fundus diseases, which means that aflibercept is used once a month for three consecutive months, and then aflibercept is used again in subsequent regular follow-ups based on fundus photography and visual acuity results.

[0004] Although anti-VEGF therapy can effectively improve the vision of patients with fundus diseases, it is not suitable for all patients with fundus diseases because frequent injections of drugs and follow-up visits are required to achieve successful and stable treatment of fundus diseases. Clinical trial results show that despite the use of continuous standard anti-VEGF treatment courses, approximately 20%-40% of wAMD patients and 15%-20% of DME patients do not respond adequately or completely to anti-VEGF treatment, and these patients need other more effective treatment drugs or methods. In addition, in long-term and frequent anti-VEGF treatment, VEGF antibodies will greatly reduce the concentration of VEGF, thereby destroying the basic protective effect of VEGF on the optic nerve and leading to the degeneration of optic nerve cells.

[0005] Prosaposin (PSAP) is a secreted lysosomal protein and a precursor of four similar proteins, namely saposin A, B, C and D, which are cofactors of sphingolipid hydrolases. PSAP is a multifunctional protein that is both intracellular and extracellular. According to previous studies, PSAP mainly plays a role in cancer development and metastasis, and its specific location and function in the retina have not been fully elucidated. Notably, Berghe et al. found that PSAP mRNA was detected in rat retinal pigment epithelial cells and retinal ganglion cells, and its upregulation coincided with the maturation of photoreceptor cells and the beginning of the phagocytic process. Despite the above findings, the expression and function of PSAP in the retina are still relatively scarce. Studies have shown that PSAP may also have neuroprotective and neurotrophic properties. For example, Kang et al. demonstrated that PSAP can inhibit tumor metastasis through terephthalic acid and endocrine stimulation of substrates p53 and THBS1. In addition, He et al. reported the protective effect of PSAP against 6-OHDA-induced oxidative stress and dopamine neurotoxicity. Furthermore, PSAP in plaque macrophages may be an important mediator of the anti-inflammatory effects of mTOR and S6K1 inhibition. Despite these interesting findings, the exact role of PSAP in retinal physiology and pathology has not been fully investigated. In our current study, we conducted a comprehensive exploration to characterize the location and function of PSAP in the retina. Our findings suggest that PSAP may be a promising potential drug for the treatment of fundus diseases.

[0006] The peptide PSAP-A, namely TALIDNNATEEILY, and the peptide PSAP-B, namely LSELIINNATEELLIKGL, are derived peptides of PSAP protein and are active fragments. Both peptides have been reported in the research literature. [1-2] , but not in the field of fundus disease treatment.

[0007] Therefore, developing more effective VEGF therapeutic drugs or methods, reducing the frequency of treatment, and achieving better neovascularization inhibition and neuroprotection effects are of great significance for the treatment of patients with fundus diseases.

[0008] References:

[0009] PSAP-A: [1] GPR37 and GPR37L1 are receptors for the neuroprotective and glioprotective factors prosaptide and prosaposin.

[0010] PSAP-B:[2]AttenuationofMPTP / MPP(+)toxicityinvivoandinvitrobyan18-merpeptidederivedfromprosaposin. Summary of the invention

[0011] In view of the above-mentioned defects of the prior art, the technical problem to be solved by the present invention is to provide a more effective VEGF treatment drug or method, reduce the frequency of treatment, and achieve better angiogenesis inhibition and neuroprotection effects.

[0012] To achieve the above objectives, the present invention provides the use of pro-sphingolipid activating protein (PSAP) as a drug for the preparation of a drug for treating fundus diseases with the effects of inhibiting neovascularization and protecting neurons, wherein the fundus diseases include but are not limited to age-related macular degeneration (AMD), diabetic retinopathy (DR), retinal vascular occlusion, and various subtypes of the above fundus diseases.

[0013] In a preferred embodiment of the present invention, the PSAP specifically uses an active derivative peptide of PSAP protein, namely, polypeptide PSAP-A, whose amino acid sequence is SEQ ID NO.1, or polypeptide PSAP-B, whose amino acid sequence is SEQ ID NO.2.

[0014] In another preferred embodiment of the present invention, the PSAP specifically adopts the amino acid sequence of PSAP protein from the Uniport database, NCBI database, Ensembl database or PDB database, including the PSAP protein of Homo sapiens, whose sequence is shown in SEQ ID NO.3, or the PSAP protein of Mus musculus, whose sequence is shown in SEQ ID NO.4, or the PSAP protein of Rattus norvegicus, whose sequence is shown in SEQ ID NO.5.

[0015] In another preferred embodiment of the present invention, the PSAP is in solution form in the prepared medicine.

[0016] In another preferred embodiment of the present invention, the concentration of PSAP in the prepared medicine is 250 nM-1 μM.

[0017] In another preferred embodiment of the present invention, the concentration of PSAP in the prepared drug is 250 nM, 500 nM or 1 μM.

[0018] In another preferred embodiment of the present invention, the injection method of the drug prepared by PSAP is intravitreal injection.

[0019] In another preferred embodiment of the present invention, the PSAP is further mixed with pharmaceutically acceptable excipients during the preparation of the drug.

[0020] In another preferred embodiment of the present invention, the pharmaceutically acceptable excipients include one or more of a pH regulator, an isotonicity regulator, an antibacterial agent, a thickener, a solubilizer, and a cosolvent.

[0021] In another preferred embodiment of the present invention, the PSAP is mixed with other drugs for treating fundus diseases during the preparation of the drug.

[0022] Technical Effects

[0023] The present invention explores and develops the use of PSAP as a new fundus drug for preparing, and for the first time discovers that PSAP is widely expressed in cells and mouse retinas, and for the first time discovers that PSAP is upregulated in in vitro cells and in vivo mouse retinas after intervention with aflibercept, and for the first time explores and discovers that PSAP has similar angiogenesis inhibition and anti-inflammatory effects as aflibercept in in vitro cells and in vivo mouse CNV models, and for the first time explores and discovers that PSAP has additional neuroprotective effects compared to aflibercept in in vitro cells and in vivo mouse light damage models, that is, it has anti-oxidative damage and anti-light damage effects. Therefore, in terms of neuroprotective effects, PSAP is superior to aflibercept.

[0024] The concept, specific structure and technical effects of the present invention will be further described below in conjunction with the accompanying drawings to fully understand the purpose, characteristics and effects of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 It is a statistical bar graph of the relative abundance of PSAP mRNA in HUVECs detected by qPCR and the expression of PSAP and its relative intensity detected by immunoblotting in a preferred embodiment of the present invention;

[0026] Figure 2 It is a statistical bar graph of the relative abundance of PSAP mRNA in ARPE-19 detected by qPCR and the expression of PSAP and its relative intensity detected by immunoblotting in a preferred embodiment of the present invention;

[0027] Figure 3 This is an immunofluorescence image of retinal sections of C57BL / 6J mice injected with PBS or aflibercept in a preferred embodiment of the present invention;

[0028] Figure 4 is a statistical bar graph of the relative abundance of PSAP in mixed samples of aqueous humor and vitreous of C57BL / 6J mice injected with PBS or aflibercept using ELISA method according to a preferred embodiment of the present invention;

[0029] Figure 5 It is an in vitro Transwell Migration Assay (TMA) image for evaluating PSAP inhibition of cell migration and a statistical bar graph of the proportion of migrated cells in the TMA according to a preferred embodiment of the present invention;

[0030] Figure 6 It is a statistical bar graph of an in vitro tube formation assay (TFA) image and the proportion of reticular structures in TFA for evaluating the inhibition of tubule formation by PSAP in a preferred embodiment of the present invention. The number of reticular structures is quantified using Image J software;

[0031] Figure 7 It is a statistical bar graph of the Fundus Fluorescein Angiography (FFA) images and the proportion of vascular leakage areas of PSAP and Aflibercept in a CNV (choroidal neovascularization) mouse model according to a preferred embodiment of the present invention;

[0032] Figure 8 It is an immunofluorescence image of the choroid flat mounts (CFM) of the CNV mouse model of a preferred embodiment of the present invention and a statistical bar graph of the relative fluorescence integrated intensity;

[0033] Fig. 9 It is a preferred embodiment of the present invention, measuring the cell viability bar graph relative to the PBS control in the 661W cell model of H2O2-induced oxidative stress damage by CCK-8 method and detecting apoptosis results by flow cytometry using Annexin V-FITC apoptosis detection kit;

[0034] Fig.10 It is a TUNEL staining image and a statistical bar graph of apoptotic cell ratio in a preferred embodiment of the present invention;

[0035] Fig.11 It is a statistical bar graph of the immunofluorescence images of retinal sections and the relative integrated fluorescence intensity in the PC layer in a preferred embodiment of the present invention for evaluating PSAP and aflibercept in a retinal light-damaged mouse model. DETAILED DESCRIPTION

[0036] The following describes several preferred embodiments of the present invention with reference to the drawings in the specification, so that the technical content is clearer and easier to understand. The present invention can be embodied in many different forms of embodiments, and the protection scope of the present invention is not limited to the embodiments mentioned in the text.

[0037] The present invention provides a protein drug for treating fundus diseases, namely, prosaposin (PSAP). The protein drug is expected to solve the technical problem that the existing aflibercept is ineffective or poor in treating patients with fundus diseases.

[0038] The fundus diseases treated by PSAP include but are not limited to age-related macular degeneration (AMD), diabetic retinopathy (DR), retinal vascular occlusion (RVOC), and various subtypes of the above fundus diseases.

[0039] The amino acid sequence of PSAP is from Uniport database, NCBI database, Ensembl database or PDB database, etc., including but not limited to the sequence used in the present invention, including polypeptide PSAP-A: SEQ ID NO.1TALIDNNATEEILY, or polypeptide PSAP-B: SEQ ID NO.2LSELIINNATEELLIKGL. In the experiments of the present invention, it was found that the inhibitory effect of PSAP-B on neovascularization was better than that of PSAP-A. In subsequent experiments to explore the neuroprotective effect of PSAP, the present invention used PSAP-B.

[0040] In addition, since PSAP-A and PSAP-B are both derivative peptides of PSAP protein and are active fragments, other PASP proteins derived from the database may also be used in the treatment of related fundus diseases, such as the PSAP protein of Homo sapiens from humans, whose sequence is shown in SEQ ID NO.3 (524 amino acids), or the PSAP protein of Mus musculus from mice, whose sequence is shown in SEQ ID NO.4 (557 amino acids), or the PSAP protein of Rattus norvegicus from mice, whose sequence is shown in SEQ ID NO.5 (554 amino acids).

[0041] The concentration of PSAP includes, but is not limited to, 250 nM, 500 nM, 1 μM, etc. used in the present invention.

[0042] The dosage form of PSAP is solution type. The injection method is intravitreal injection. The drug also includes pharmaceutically acceptable excipients. The excipients include any one or more of pH regulators, isotonicity regulators, antibacterial agents, thickeners, solubilizers, cosolvents, etc.

[0043] PSAP can be used as a single agent to treat fundus diseases or in combination with other drugs.

[0044] Through in vitro and in vivo studies, we observed that aflibercept upregulated the expression of PSAP, which was widely distributed in the mouse fundus structures (including retina, RPE, and choroid).

[0045] In vitro cell experiments found that PSAP can inhibit HUVECs cell migration and tubule formation, and its effect is similar to that of aflibercept.

[0046] In an in vivo CNV mouse model, PSAP exhibited anti-angiogenic and anti-inflammatory properties, with effects similar to those of aflibercept.

[0047] In vitro cell experiments found that PSAP was better than aflibercept in protecting 661W cells from oxidative stress damage and apoptosis caused by H2O2.

[0048] In the in vivo light damage model of mice, PSAP has an additional protective effect on photoreceptor cells compared to aflibercept, which is superior to aflibercept.

[0049] According to the above experimental results, PSAP has great clinical translational value for the development of drugs to treat fundus diseases. PSAP has an inhibitory effect on neovascularization equivalent to that of Aflibercept, and also has a neuroprotective effect superior to that of Aflibercept (Aflibercept does not have a neuroprotective effect).

[0050] Example 1. Expression of PSAP in vitro and in vivo and its expression under the intervention of aflibercept.

[0051] 1.1 Materials and methods

[0052] HUVECs (Human Umbilical Vein Endothelial Cells) were obtained from the Shanghai Institute of Biological Sciences and cultured in PromoCell medium containing 20% ​​FBS at 37°C and 5% CO2. Experiments were performed on cells with less than 6 passages in culture. HUVECs were treated with 20 ng / mL VEGFA and / or 1 mg / ml aflibercept for 12 or 24 hours at 37°C.

[0053] ARPE-19 (Adult Retinal Pigment Epithelial Cell Line-19, human retinal pigment epithelial cells) cells were purchased from the American Type Culture Collection (ATCC, USA) and cultured in DMEM (Gibco, Life Technologies, Carlsbad, CA) containing 10% FBS at 37°C and 5% CO2. Cells were seeded in 96-well plates and treated with 20 ng / mL VEGFA and / or NaIO3 (2 mM) for 12 hours or 24 hours.

[0054] Total RNA was extracted from cells using Reagents (Takara Bio, Inc., Otsu, Japan) were used and operated according to the manufacturer's guidelines. Reverse transcription (RT) for cDNA synthesis was performed using PrimeScript RT Mastermix (Takara Bio, Inc.) according to the manufacturer's instructions. Quantitative polymerase chain reaction (qPCR) analysis was performed using the ABI7900HT system (Applied Biosystems; Thermo Fisher Scientific, Inc.) and Green PCR Master mix (TakaraBio, Inc.) according to the manufacturer's protocol. Thermocycling parameters included an initial denaturation at 95°C for 30 min, followed by 40 cycles of denaturation at 94°C for 5 s and annealing / extension at 60°C for 34 s, and a final extension at 72°C for 10 min. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a reference gene for normalization, and the relative expression level of PSAP was determined using the 2-ΔΔCq method.

[0055] HUVECs and ARPE-19 cells were collected and quantified using the BCA method. Then, approximately 10 μg of protein was loaded onto an 8% to 15% SDS-PAGE gel and transferred to a PVDF membrane (Merck Millipore, Billerica, MA, United States). The membrane was then blocked in Tris-buffered saline Tween-20 (TBST) containing 5% skim milk powder for 1 hour, followed by incubation with primary antibodies overnight at 4°C: PSAP (Novus Biologicals, NB300-318, 1:1000) (Proteintech, 1:1000) and GAPDH (Proteintech, 1:1000). After the membrane was washed with TBST, it was incubated with a horseradish peroxidase (HRP)-conjugated secondary antibody (Proteintech, 1:5000) for 1 hour. Subsequently, the membrane was exposed to a molecular imaging system (Amersham Imager 600, GE Healthcare, Buckinghamshire, United Kingdom).

[0056] PSAP expression in mouse vitreous (VB) and aqueous humor (AH) was assessed by enzyme-linked immunosorbent assay (ELISA). After euthanasia, VB and AH tissues were placed in separate wells and processed according to the guidelines provided by the manufacturer of the ELISA kit. The optical density (OD) of each sample was measured at a wavelength of 450 nm to determine the extent of PSAP expression.

[0057] C57BL / 6J female mice aged 6 to 8 weeks were used in the experiment, which were purchased from Shanghai, China. The water and food for all mice were sterilized. All animal experimental procedures were performed in accordance with the guidelines of the Association for Research in Vision and Ophthalmology on the ethical use of animals. According to the experimental protocol, drugs such as PBS, 25 mg / mL aflibercept, and 25 mg / mL PSAP synthetic peptide were injected intravitreally.

[0058] The retina of the eye was sliced ​​with a thickness of 10 μm using a slicer and analyzed by immunofluorescence staining. After fixation, the samples were blocked with a PBS solution containing 0.3% TritonX-100 and 5% goat serum albumin (Beyotime) for 1 hour. Subsequently, the sections were incubated overnight at 4°C with primary antibodies against PSAP. Afterwards, the sections were stained with secondary antibodies (Proteintech, 1:1000) for 1 hour, and the retinal sections were observed using a confocal microscope (Leica, USA).

[0059] 1.2 Experimental Results

[0060] First, we investigated the expression of PSAP in HUVECs and ARPE-19 and its abundance changes after aflibercept intervention. VEGFA-induced HUVECs proliferation mimics the formation of new blood vessels in the fundus. qPCR analysis of PSAP mRNA levels in HUVECs showed that VEGFA led to downregulation of PSAP expression, while aflibercept intervention significantly reversed this effect ( Figure 1 A). In addition, Western blot analysis of PSAP expression and subsequent quantitative analysis using Image J software showed that VEGFA led to downregulation of PSAP expression, while aflibercept led to upregulation of PSAP expression ( Figure 1 B). Figure 1 (A) Statistical bar graph of the relative abundance of PSAP mRNA in HUVECs detected by qPCR. HUVECs (human umbilical vein endothelial cells) proliferate under the stimulation of VEGFA. VEGFA: 20 ng / mL. Aflibercept: 1 mg / mL. (B) The expression of PSAP in (A) and its relative intensity were detected by immunoblotting.

[0061] In addition to neovascularization, retinal degeneration is also a common clinical manifestation of fundus disease. We treated ARPE-19 with sodium iodate (NaIO3) to simulate retinal degeneration. qPCR analysis of PSAP mRNA levels in ARPE-19 cells showed that NaIO3 downregulated PSAP expression, while aflibercept treatment upregulated PSAP expression ( Figure 2 A). Western blot analysis of PSAP expression in ARPE-19 cells and subsequent quantitative analysis using Image J software also confirmed that NaIO3 down-regulated PSAP expression, while aflibercept up-regulated PSAP expression ( Figure 2 B). Figure 2 (A) Statistical bar graph of the relative abundance of PSAP mRNA in ARPE-19 detected by qPCR. NaIO3 (sodium iodate) induced degeneration of ARPE-19 (adult retinal pigment epithelial cell line-19). NaIO3: 2mM. Aflibercept: 1mg / mL. (B) The expression of PSAP in (A) and its relative intensity were detected by immunoblotting. GAPDH: control.

[0062] Subsequently, we verified the expression of PSAP in the mouse retina and evaluated whether it was upregulated after aflibercept treatment. Immunofluorescence staining of PSAP in retinal sections of C57BL / 6J mice that received intravitreal injections of PBS or aflibercept showed that PSAP was widely expressed in mouse fundus structures (retina, retinal pigment epithelium, and choroid layer) ( Figure 3A), and expression increased in retinal sections after aflibercept intervention ( Figure 3 B). Figure 3 Immunofluorescence images of PSAP staining in retinal sections of C57BL / 6J mice injected with PBS (A) or aflibercept (B). PSAP: orange. Nuclei: DAPI, blue. Scale bar: 100 μm.

[0063] To further quantify PSAP expression, we used ELISA to measure PSAP concentrations in aqueous humor and vitreous samples of C57BL / 6J mice that received intravitreal injections of PBS or aflibercept. The results showed that aflibercept significantly upregulated PSAP expression in aqueous humor and vitreous samples of C57BL / 6J mice (P<0.01)( Figure 4 ). Figure 4 . Statistical histogram of the relative abundance of PSAP in aqueous humor and vitreous mixed samples of C57BL / 6J mice injected with PBS or aflibercept measured by ELISA.

[0064] Example 2. Inhibitory effect of PSAP on neovascularization in vitro and in vivo.

[0065] 2.1 Materials and methods

[0066] According to the experimental design, cells were treated with various agents, including H2O2, aflibercept (1 mg / ml), and different concentrations of PSAP synthetic peptides (250 nM, 500 nM, and 1 μM). Two PSAP synthetic peptides, PSAP-A: TALIDNNATEEILY and PSAP-B: LSELIINNATEELLIKGL, were used for research purposes and obtained from Nanjing Tengger Biotechnology Co., Ltd.

[0067] HUVECs were collected and resuspended in serum-free medium and then seeded in the upper chamber of a 24-well insert with a pore size of 8 μm (Corning, NY, USA) at a density of 1×105 cells / 0.2 mL. Subsequently, 20 ng / mL of VEGFA, 1 mg / mL or 0.5 mg / mL of aflibercept, and 250 nM or 1 μM of PSAP-derived peptides (PSAP-A or PSAP-B) were added to the lower chamber of the corresponding wells. After 24 hours, non-migrated cells on the upper surface of the membrane were removed with a cotton swab. Migrated cells were fixed with 4% PFA for 15 minutes and then stained with 0.1% (w / v) crystal violet (Sigma) for 15 minutes. Five fields of view were randomly selected for each well, observed under an inverted microscope (Nikon) and cell counting was performed using ImageJ software (Bethesda).

[0068] Matrigel (BD Biosciences, San Jose, CA, USA) was thawed overnight at 4°C. Pipette tips (200 μL) and 96-well plates were also cooled overnight at 4°C and kept on ice throughout the experiment. 60 μL of Matrigel was dispensed into each well and then incubated at 37°C for 30 minutes to allow the matrix to polymerize. The pretreated HUVECs were then resuspended and counted to achieve the desired cell density of 1.5 × 104 cells per well. After incubation at room temperature for 15 minutes, the plates were transferred to an incubator at 37°C. After incubation for 4 to 6 hours, the formation of capillary-like tubes was assessed by counting the number of grids (closed circles) in 5 randomly selected optical fields at ×40 or ×100 magnification using an Olympus BX51 + DP70 fluorescence microscope (Olympus Corporation, Tokyo, Japan).

[0069] C57BL / 6J female mice aged 6 to 8 weeks were used in the experiment, which were purchased from Shanghai, China. The water and food for all mice were sterilized. All animal experimental procedures were performed in accordance with the guidelines of the Association for Research in Vision and Ophthalmology on the ethical use of animals. According to the experimental protocol, drugs such as PBS, 25 mg / mL aflibercept, and 25 mg / mL PSAP synthetic peptide were injected intravitreally.

[0070] C57BL / 6J mice were anesthetized by intraperitoneal injection of 1.5% sodium pentobarbital (100 μL / 20 g), and the pupils were dilated using 0.5% tropicamide and 0.5% norepinephrine hydrochloride eye drops. Laser photocoagulation (532 nm argon laser, 100 mW, 100 ms, 75 μm) was performed at the 5 and 11 o'clock positions around the optic disc while avoiding blood vessels. The appearance of bubbles was considered a positive indication of rupture of Bruch's membrane by laser irradiation.

[0071] Ten days after laser injury, FFA (fluorescein fundus angiography) was performed and then euthanized. Mice were anesthetized, pupils were dilated, and 2% sodium fluorescein (Fluorescite, Alcon, Tokyo, Japan) was injected intraperitoneally. FFA images were taken at 2-minute intervals and subsequently analyzed using ImageJ software (NIH, USA).

[0072] Choroidal flat mounts were performed on the eyes and analyzed by immunofluorescence staining. After fixation, the samples were blocked with PBS solution containing 0.3% Triton X-100 and 5% goat serum albumin (Beyotime) for 1 hour. Subsequently, the sections were incubated overnight at 4°C with primary antibodies against CD31 and F4 / 80, and DAPI was used to stain the nuclei. Afterwards, the sections were stained with secondary antibodies (Proteintech, 1:1000) for 1 hour, and the choroidal flat mounts were observed using a confocal microscope (Leica, USA).

[0073] 2.2 Experimental Results

[0074] First, the potential anti-angiogenic effect of PSAP was evaluated by in vitro experiments, including Transwell Migration Assay (TMA) and Tube Formation Assay (TFA). HUVECs were used for in vitro experiments. VEGFA was used to stimulate cell migration and tubule formation in TMA and TFA. Two synthetic peptides derived from PSAP, PSAP-A and PSAP-B (see 2.1 Materials and Methods for details), were used to study their effects on inhibiting cell migration and tubule formation at different concentrations and compared with aflibercept.

[0075] Quantification of migrated HUVECs using crystal violet staining ( Figure 5 A), and Image J software was used for image quantification ( Figure 5 B). The results showed that PSAP-B exhibited a stronger effect than PSAP-A in inhibiting cell migration, and the potency of PSAP-B was comparable to that of Aflibercept. Figure 5 .(A) Images of in vitro Transwell Migration Assay (TMA) for evaluating PSAP inhibition of cell migration. The number of migrating cells (HUVECs) was determined using crystal violet staining. PSAP-A and PSAP-B are two isoforms of PSAP protein. PBS: control group. VEGFA: 20 ng / mL. Low concentration of aflibercept: 0.5 mg / mL. High concentration of aflibercept: 1 mg / mL. Low concentration of PSAP-A: 250 nM. High concentration of PSAP-A: 1 μM. Low concentration of PSAP-B: 250 nM. High concentration of PSAP-B: 1 μM. Scale bar: 50 μm. (B) Statistical bar graph of the proportion of migrating cells in TMA. The number of cells was quantified using Image J software.

[0076] The amount of reticular structures in TFA was used to evaluate the ability to inhibit tubule formation ( Figure 6 A) and quantified using Image J software ( Figure 6 B) The analysis showed that PSAP-B was more effective than PSAP-A in inhibiting tubule formation and that the potency of PSAP-B was comparable to that of aflibercept. Figure 6 (A) In vitro Tube Formation Assay (TFA) images used to evaluate the inhibition of tubule formation by PSAP. Cells: HUVECs. PBS: control group. VEGFA: 20 ng / mL. Low concentration of Aflibercept: 0.5 mg / mL. High concentration of Aflibercept: 1 mg / mL. Low concentration of PSAP-A: 250 nM. High concentration of PSAP-A: 1 μM. Low concentration of PSAP-B: 250 nM. High concentration of PSAP-B: 1 μM. Scale bar: 100 μm. (B) Statistical bar graph of the proportion of reticular structures in TFA. The number of reticular structures was quantified using Image J software.

[0077] Subsequently, a C57BL / 6J CNV mouse model was established to evaluate the anti-angiogenic effects of PSAP-B and aflibercept in vivo. Fundus fluorescein angiography (FFA) images showed ( Figure 7 A), CNV mice (Group 2) had obvious vascular leakage areas, which were significantly reduced after treatment with aflibercept or PSAP-B. Quantitative evaluation of the leakage areas showed that PSAP-B could reduce fundus vascular leakage to a similar extent as aflibercept (P>0.05) ( Figure 7 B). Figure 7 (A) Fundus Fluorescein Angiography (FFA) images of PSAP and Aflibercept in CNV (choroidal neovascularization) mouse model. Dashed circle: vascular leakage area. Aflibercept: 1 mg / mL. PSAP-B: 1 μM. (B) Statistical bar graph of the proportion of vascular leakage area.

[0078] Subsequently, choroid flat mounts (CFM) were prepared and further analyzed for neovascularization areas (CD31, red) and inflammation areas (F4 / 80, green) ( Figure 8 ). Figure 8.Immunofluorescence images of choroid flat mounts (CFM) of CNV mouse model and statistical bar graphs of relative fluorescence integrated intensity. Aflibercept: 1 mg / mL. PSAP-B: 1 μM. Cell nucleus: DAPI (blue). Neovascularization area: CD31 (red). Inflammation area: F4 / 80 (green). Scale bar: 100 μm. Error bars represent the standard deviation value of each test. Analysis of immunofluorescence images and statistical bar graphs of relative fluorescence integrated intensity showed that PSAP-B could inhibit neovascularization and reduce inflammation, and its effect was comparable to that of aflibercept (P>0.05).

[0079] Therefore, PSAP is a novel therapeutic agent with the potential to inhibit angiogenesis both in vitro and in vivo, similar to the effect of aflibercept.

[0080] Example 3. Neuroprotective effects of PSAP in vitro and in vivo.

[0081] 3.1 Materials and methods

[0082] 661W cells were cultured in DMEM supplemented with FBS and 1% penicillin / streptomycin at 37°C and 5% CO2. According to the experimental design, cells were treated with various agents, including H2O2, aflibercept (1 mg / ml), and different concentrations of PSAP synthetic peptides (250 nM, 500 nM, and 1 μM). Two PSAP synthetic peptides, PSAP-A: TALIDNNATEEILY and PSAP-B: LSELIINNATEELLIKGL, were used for research purposes and were obtained from Nanjing Tengger Biotechnology Co., Ltd.

[0083] 661W cells were seeded into 96-well plates at a concentration of 1×104 cells / well and incubated at 37°C. After aspirating the conditioned medium, 100 μL of fresh cell counting kit 8 (CCK-8) solution (Dojindo Molecular Technologies, Inc., Kunamoto, Japan) in serum-free RPMI-1640 medium was added to each well. Subsequently, incubated at 37°C in the dark for 0.5 hours according to the manufacturer's instructions. The absorbance was read at 450 nm using a microplate reader (Infinite F50 microplate reader, Swiss). The experimental procedure was performed in six replicate wells and repeated at least twice.

[0084] Cell apoptosis was assessed using the Annexin V-FITC apoptosis detection kit (Beyotime, Nantong, China) according to the manufacturer's instructions. ARPE-19 cells were seeded in 6-well plates at a concentration of 2.5 × 106 cells / mL. After 48 h of drug treatment, cells were collected and analyzed using a flow cytometer (FACSPartec, Germany) according to the manufacturer's guidelines.

[0085] To study the effects of aflibercept and PSAP synthetic peptide on cell apoptosis, 661W cells were plated at 3 × 10 3 Cells were seeded in 96-well plates at a density of 10 cells / mL. Before treatment, cells were exposed to H2O2 (50 μM, Sigma-Aldrich, Merck KGaA) for 4 h. The medium was then replaced and cells were treated with 1 mg / mL of aflibercept or 1 μM of PSAP synthetic peptide for 24 h. The Annexin V apoptosis detection kit (88-8102-72, Invitrogen TM , United States) and TUNEL staining to assess the apoptotic status of cells.

[0086] C57BL / 6J female mice aged 6 to 8 weeks were used in the experiment, which were purchased from Shanghai, China. The water and food for all mice were sterilized. All animal experimental procedures were performed in accordance with the guidelines of the Association for Research in Vision and Ophthalmology on the ethical use of animals. According to the experimental protocol, drugs such as PBS, 25 mg / mL aflibercept, and 25 mg / mL PSAP synthetic peptide were injected intravitreally.

[0087] C57BL / 6J mice were exposed to a light intensity of 5000 ± 200 Lx for 6 h in a custom-made light box. After light treatment, the mice were returned to their original light-dark cycle environment for 1 week.

[0088] The retina of the eye was sliced ​​at 10 μm thickness using a slicer and analyzed by immunofluorescence staining. After fixation, the samples were blocked with a PBS solution containing 0.3% Triton X-100 and 5% goat serum albumin (Beyotime) for 1 hour. Subsequently, the sections were incubated overnight at 4°C with primary antibodies against RHO (1:200, MA1-722, Thermofisher Scientific). Afterwards, the sections were stained with secondary antibodies (Proteintech, 1:1000) for 1 hour, and the retinal sections were observed using a confocal microscope (Leica, USA).

[0089] 3.2 Experimental Results

[0090] Fundus disease and other eye diseases such as glaucoma lead to progressive damage of the visual pathway, affecting the photoreceptor cells (PCs), bipolar cells, and retinal ganglion cells (RGCs) layers. Alleviating and repairing retinal neuronal damage is essential for the treatment of fundus disease. We compared the retinal neuroprotective effects of PSAP and aflibercept through a series of in vitro and in vivo experiments. The 661W cell line, a mouse retinal ganglion precursor-like cell line, was used for in vitro evaluation.

[0091] Hydrogen peroxide (H2O2) can induce oxidative stress damage and apoptosis in cells. The cell viability of 661W cells treated with H2O2 was measured by CCK-8 method. Compared with the PBS control group, the results showed that PSAP-B was more effective than aflibercept in maintaining cell viability (P<0.05) ( Fig. 9 A). Subsequently, the apoptosis of 661W cells treated with H2O2 was evaluated using the Annexin V-FITC apoptosis detection kit ( Fig. 9 B). Fig. 9 (A) Cell viability bar graph relative to PBS control in the 661W cell model of H2O2-induced oxidative stress injury measured by CCK-8 method. 661W: mouse retinal ganglion cell line. H2O2: 50μM. Aflibercept: 1mg / mL. PSAP-B: 1μM. (B) Apoptosis results were detected by flow cytometry using Annexin V-FITC apoptosis detection kit. H2O2: 50μM. Low concentration of PSAP-B: 250nM. Medium concentration of PSAP-B: 500nM. High concentration of PSAP-B: 1μM. UL: upper left quadrant, dead cells. UR: upper right quadrant, non-surviving apoptotic cells. LL: lower left quadrant, normal cells. LR: lower right quadrant, surviving early apoptotic cells. Flow cytometry results showed that PSAP-B reduced H2O2-induced early apoptosis (LR, lower right quadrant), and the effect was enhanced with increasing PSAP-B concentrations.

[0092] In addition, TUNEL staining was used to visualize apoptotic 661W cells (stained red) after H2O2 treatment ( Fig.10 A). Statistical analysis of the proportion of apoptotic 661W cells showed that PSAP-B significantly reduced H2O2-induced apoptosis, and its effect was stronger than that of aflibercept (P<0.05) ( Fig.10 B). Fig.10(A) TUNEL staining images. TUNEL: terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling. Cells: 661W. H2O2: 50μM. Aflibercept: 1mg / mL. PSAP-B: 1μM. Nuclei: DAPI (blue). Apoptotic cells: TUNEL, red. Scale bar: 50μm. (B) Statistical bar graph of apoptotic cell ratio. *: P<0.05.

[0093] To further investigate the anti-light damage properties of PSAP, a retinal light damage mouse model was established using 5000±200Lx light. RHO (Rhodopsin) is expressed in PCs and converts photons into chemical signals, triggering biological processes in the retinal nervous system. Immunofluorescence staining of RHO in retinal sections of the light damage mouse model showed that strong light can damage PCs, while PSAP-B can protect PCs from light-induced damage, while aflibercept did not show this protective effect (P<0.05) ( Fig.11 ). Fig.11 .(A) Immunofluorescence images of retinal sections evaluating PSAP and aflibercept in a mouse model of retinal light damage. Cell nuclei: DAPI (blue). PC (Photoreceptor Cells) layer: dotted box, RHO (Rhodopsin) (red). Scale bar: 100μm. (B) Statistical bar graph of relative fluorescence integrated intensity in the PC layer. *: P<0.05. Aflibercept: 1mg / mL. PSAP-B: 1μM. Error bars represent the standard deviation value of each test.

[0094] Therefore, PSAP exhibited neuroprotective effects against oxidative stress damage and light-induced retinal neuronal damage in vitro and in vivo, and its effect was superior to that of aflibercept.

[0095] The preferred specific embodiments of the present invention are described in detail above. It should be understood that ordinary technicians in the field can make many modifications and changes based on the concept of the present invention without creative work. Therefore, all technical solutions that can be obtained by technicians in the technical field based on the concept of the present invention through logical analysis, reasoning or limited experiments on the basis of the prior art should be within the scope of protection determined by the claims.

Claims

1. Use of pro-sphingolipid activator protein PSAP as a drug for treating fundus diseases with angiogenesis inhibition and neuroprotective effects, characterized in that: The fundus diseases include, but are not limited to, age-related macular degeneration (AMD), diabetic retinopathy (DR), retinal vascular occlusion, and various subtypes of the above fundus diseases.

2. The use according to claim 1, characterized in that The PSAP specifically uses an active derivative peptide of PSAP protein, namely, polypeptide PSAP-A, whose amino acid sequence is SEQ ID NO.1, or polypeptide PSAP-B, whose amino acid sequence is SEQ ID NO.

2.

3. The use according to claim 1, characterized in that The PSAP specifically adopts the amino acid sequence of PSAP protein from the Uniport database, NCBI database, Ensembl database or PDB database, including the PSAP protein of Homosapiens, whose sequence is shown in SEQ ID NO.3, or the PSAP protein of Mus musculus, whose sequence is shown in SEQ ID NO.4, or the PSAP protein of Rattus norvegicus, whose sequence is shown in SEQ ID NO.

5.

4. The use according to claim 1, characterized in that The PSAP is in solution form in the prepared medicine.

5. The use according to claim 3, characterized in that The concentration of PSAP in the prepared medicine is 250nM-1μM.

6. The use according to claim 4, characterized in that The concentration of PSAP in the prepared medicine is 250 nM, 500 nM or 1 μM.

7. The use according to claim 1, characterized in that The administration method of the drug prepared by PSAP is intravitreal injection.

8. The use according to claim 1, characterized in that The PSAP is also mixed with pharmaceutically acceptable excipients during the preparation of the drug.

9. The use according to claim 8, characterized in that The pharmaceutically acceptable excipients include one or more of a pH regulator, an isotonicity regulator, an antibacterial agent, a thickener, a solubilizer, and a cosolvent.

10. The use according to claim 1, characterized in that The PSAP is mixed with other drugs for treating fundus diseases when preparing the drug.